<DOC>
	<DOCNO>NCT01745302</DOCNO>
	<brief_summary>The investigator perform randomize , double-blind control , prospective study method observation Traditional Chinese Medicine combine targeted therapy prolong efficacy long-term survival advance pulmonary Adenocarcinoma patients.The investigator plan involve 404 case observation 3 year ( 202 case group ) , expect integrate TCM combine targeted therapy well efficacy prolong progression-free survival time , overall survival , improve QOL patient target therapy .</brief_summary>
	<brief_title>Efficacy Study Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI Advanced Pulmonary Adenocarcinoma</brief_title>
	<detailed_description>At present , third generation platinum-based regimen ( NCCN clinical practice guideline recommend use vinorelbine gemcitabine , Taxol , etc . ) first-line treatment advance lung cancer patient . Its effective rate 20-30 % , median survival time 7-9 month , 1-year 2-year survival rate 31-36 % 10-13 % respectively . The efficacy reach platform difficult breakthrough . Epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKIs ) Iressa Erlotinib prove effective first second line therapy advance non-small cell lung cancer ( NSCLC ) .First-SIGNAL IPASS research lay first-line status gefitinib treatment NSCLC progression-free survival time maintain 9-10 month . EGFR-TKIs treatment simple , well tolerate , drug side effect , etc . There also rash , diarrhea adverse reaction , affect quality life patient serious even give patient great deal pain.Literature preliminary study show traditional Chinese medicine ( TCM ) prolong survival time improve quality life QOL , high-level evidence need . The investigator perform randomize , double-blind control , prospective study Advanced Pulmonary Adenocarcinoma patient stage Ⅲa～Ⅳ . Patients randomize observational group ( TCM granules plus first-line targeted therapy TCM granule plus second-line targeted therapy ) , control group ( TCM placebo plus first-line targeted therapy TCM placebo plus second-line targeted therapy ) . The investigator observe 6 month regular follow-up arrange . The primary efficacy assessment : PFS ( progression-free survival） ; Secondary efficacy assessment : ( 1 ) OS ( overall survival ) ; ( 2 ) Objective response rate ; ( 3 ) TTP（Time-to-Progression） ; ( 4 ) QOL ( Functional Assessment Cancertherapy-lung , FACT-L4.0 scale ; Lung Cancer Symptom Scale , LCSS ) ; ( 5 ) efficacy assessment : 1 ) TCM symptom change ; 2 ) Toxicity , side effect security treatment assess time . The investigator expect integrate TCM combine targeted therapy well efficacy prolong progression-free survival time , overall survival , improve QOL patient target therapy . Therefore study provide evidence optimize promote integrate TCM combine Western Medicine treatment .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Pathologically cytologically confirm stage IIIaIV NSCLC adenocarcinoma histology ; 2 . Patient mutate EGFR subject first line target thearapy；patients receive least one cycle platinumcontaining chemotherapy regimen disease progression/recurrence， intolerant/refuse proceed chemotherapy explore second line target therapy ; 3 . Physical status score ( ECOG PS ) ≤ 2 score ; 4 . Age ≥18 year old ; 5 . Estimated life expectancy least 12 week ; 6 . Participants major organ dysfunction : hemoglobin ≥9 g/dL , absolute neutrophil count ( ANC ) ≥1.5*109/L , platelet ≥100 *109/L , bilirubin ≤1.5ULN , alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 upper limited number ( ULN ) ( AP , AST , ALT ≤5ULN acceptable liver tumor involvement ) .INR≤1.5 , APTT normal range ( 1.2DLN1.2ULN ) , creatinine ≤1.5ULN ; 7 . Informed consent patient . 1 . Patient malignant tumor except NSCLC 5 year previous study entry . 2 . Wild type EGFR ; already receive target treatment anticancer treatment palliative radiotherapy finish 4 week operation 4 week first drug administration ; 3 . Estimated life expectancy le 12 week ; 4 . Brain metastasis ( control brain metastasis steroid free need exclude ) . 5 . History cardiovascular disease : Congestive Heart Failure &gt; grade II NYHA . Unstable angina patient ( angina symptom rest ) new occurrence angina ( begin last 3 month ) myocardial infarction happen last 6 month ; 6 . Pregnant child breast feeding woman ; 7 . Mental cognitive disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>traditional Chinese medicine</keyword>
	<keyword>EGFR-TKI</keyword>
</DOC>